Jennifer Cannon, Ph.D., has been named the Senior Vice President and Global Head of Lonza’s Mammalian Biologics Business Unit.
In her role, Jennifer will oversee the strategy and growth of the business unit.
Cannon has more than 18 years of business leadership and market development experience in the biopharma and life science industries. She was previously Vice President, Operations Commercial Development at AbbVie: where she developed and executed the growth strategy for a broad range of Abbvie’s CMO services and technologies, including mammalian biologics, fill finish, ADC, microbial fermentation, and oral solid dose.
Prior to Abbvie, Cannon was Vice President of Commercial Operations for Ajinomoto’s contract manufacturing organization where she led the Commercial Development and Sales organizations driving strategic growth for their biologics drug substance, fill finish, and API manufacturing divisions. Prior to Ajinomoto, Jennifer was Business Director of Protein Production and Analysis at Thermo Fisher Scientific, where she led product and service management business teams.
Cannon received her Ph.D. in Pharmacology from Johns Hopkins University, School of Medicine, a M.S. in Molecular Biology from the Salk Institute and a B.S. in Biochemistry from the University of California, San Diego. She attained her post-doctoral training at Genentech in the Department of Oncology.